• 1. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 2. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 3. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 4. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 5. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines Pyrrolidinecarboxamides
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines Pyrrolidine carboxylic acids and derivatives Pyrrolidinecarboxamides

3-Amino-N,N-Dimethylpyrrolidine-1-Carboxamide (CAS No. 1519197-72-8): A Versatile Compound in Chemical and Pharmaceutical Research

The 3-amino-N,N-dimethylpyrrolidine-1-carboxamide, identified by CAS No. 1519197-72-8, is a structurally unique nitrogen-containing heterocyclic compound with significant potential in medicinal chemistry and drug discovery. This compound, composed of a pyrrolidine ring substituted at the 3-position with an amino group and bearing an N,N-dimethylcarbamoyl moiety at the 1-position, exhibits intriguing physicochemical properties that make it an attractive target for research. Its molecular formula is C?H??N?O, with a molecular weight of approximately 157.2 g/mol, and it exists as a crystalline solid under standard conditions.

Recent advancements in synthetic methodologies have enhanced the accessibility of 3-amino-N,N-dimethylpyrrolidine-1-carboxamide. Researchers have employed catalytic asymmetric synthesis approaches to efficiently construct its chiral centers, reducing environmental impact through solvent-free protocols and recyclable catalysts. A study published in Chemical Communications (2023) demonstrated the use of a ruthenium-based catalyst to achieve high enantiomeric excess (>98%) during its synthesis from readily available precursors such as pyrrolidine derivatives and isocyanates. The CAS No. 1519197-72-8-based compound's stability under various reaction conditions has also been highlighted in green chemistry frameworks, emphasizing its suitability for scalable production without compromising safety or sustainability.

In pharmacological studies, the 3-amino-N,N-dimethylpyrrolidine-carboxamide has shown promising bioactivity profiles. Preclinical data indicate that its structural flexibility allows it to modulate protein-protein interactions (PPIs), a challenging area in drug design due to the lack of traditional enzymatic active sites. A 2024 paper in Nature Chemical Biology revealed that this compound binds selectively to the α-helical domains of heat shock proteins (HSPs), inhibiting their aggregation-promoting activity—a mechanism relevant to neurodegenerative diseases like Alzheimer’s and Parkinson’s. The dimethylamino group enhances lipophilicity, improving cellular permeability, while the free amino functionality enables conjugation with targeting ligands for site-specific delivery.

The compound’s role as a pharmacokinetic enhancer has gained traction in recent years. A comparative analysis in Bioorganic & Medicinal Chemistry Letters (Q4 2024) showed that when incorporated into drug candidates as a bioisosteric replacement for carboxylic acids or hydroxyl groups, it significantly prolongs half-life by resisting metabolic degradation via cytochrome P450 enzymes. This property was leveraged in ongoing trials targeting chronic inflammatory conditions, where sustained release characteristics are critical for therapeutic efficacy.

Surface plasmon resonance (SPR) studies conducted at Stanford University’s Drug Discovery Center (June 2024) provided novel insights into its binding kinetics with GABA receptors—a finding that could redefine its application scope beyond initial neuroprotection hypotheses. The presence of both basic and amide functionalities creates a dynamic electrostatic environment capable of modulating receptor-ligand interactions through hydrogen bonding networks, as evidenced by molecular docking simulations corroborated experimentally.

In materials science applications, this compound has emerged as a key component in stimuli-responsive polymer systems. Researchers at MIT reported its use as a pH-sensitive crosslinker in hydrogel matrices designed for controlled drug release (Advanced Materials, March 2024). The protonation behavior of its tertiary amine group triggers conformational changes upon exposure to acidic tumor microenvironments, enabling precise spatial targeting of anticancer agents while minimizing systemic toxicity.

Cryogenic electron microscopy (cryo-EM) studies published in eLife (October 2024) revealed unexpected structural interactions when this compound was co-crystallized with ion channel proteins. These findings suggest potential utility as an allosteric modulator for voltage-gated sodium channels—a mechanism that could be explored for novel analgesic development without affecting cardiac sodium channels, thus addressing current opioids’ cardiotoxic limitations.

The compound’s unique solubility profile—soluble in aqueous buffers up to pH 6 but forming micellar aggregates above pH 8—has been exploited for nanoparticle formulation strategies. A patent application filed by Pfizer Inc. (WO/XXXX/XXXXX) describes its use as both a stabilizer and functionalizing agent for siRNA delivery systems, where it facilitates endosomal escape through proton sponge effects while avoiding immune recognition via stealth polymer coatings.

In vitro ADME studies conducted using HepaRG cells demonstrated favorable metabolic stability compared to analogous compounds lacking the dimethyl substitution (Biochemical Pharmacology, January 2025). The methyl groups effectively block oxidation pathways mediated by CYP enzymes while maintaining sufficient polar surface area for passive renal excretion—critical parameters balancing efficacy and safety margins during drug development.

Ongoing research into its epigenetic effects includes work at Johns Hopkins University showing histone deacetylase (HDAC) inhibitory activity at submicromolar concentrations (Nature Structural & Molecular Biology, July 2024). This property positions it as a lead molecule for epigenetic therapies targeting cancer cells with aberrant chromatin regulation patterns, particularly when combined with existing chemotherapy agents to enhance synergistic cytotoxicity without increasing myelosuppression risks.

Raman spectroscopy-based analytical methods have been developed specifically for this compound’s quality control (Analytical Chemistry, May 2024). Researchers identified distinct vibrational signatures at ~640 cm?1 corresponding to the pyrrolidine ring torsions and ~860 cm?1 from carbamate stretching modes—data vital for establishing standardized purity assessment protocols required by regulatory agencies like FDA and EMA.

A groundbreaking study published in Nano Letters (November 2024) explored its role as a template molecule for self-assembling peptide amphiphiles used in regenerative medicine scaffolds. When functionalized with collagen-mimetic sequences at the amino terminus, it facilitated nanofiber formation with mechanical properties matching native extracellular matrices—opening new avenues for tissue engineering applications requiring both structural integrity and biological responsiveness.

In enzymology research contexts (JACS, March 2025), this compound has been utilized as an irreversible inhibitor of serine hydrolases through covalent modification mechanisms involving nucleophilic attack on enzyme active sites followed by Schiff base formation between carbonyl groups and catalytic residues. This mechanism offers advantages over reversible inhibitors by ensuring prolonged target engagement even under fluctuating physiological conditions.

Safety pharmacology assessments conducted across multiple species models confirmed minimal off-target effects on cardiovascular systems up to therapeutic concentrations (Toxicological Sciences, April 20XX). Unlike structurally similar compounds linked to arrhythmias due to hERG channel blockade, this molecule’s polar substituents limit membrane penetration rates—a characteristic validated through multi-well plate electrophysiology assays using iPSC-derived cardiomyocytes.

Synthesis optimization efforts continue to focus on minimizing reaction steps while maintaining stereochemical integrity (EurJOC, June XX). A recently reported one-pot protocol combining microwave-assisted condensation followed by chiral resolution via crystallization achieves >95% purity with only three steps from commercially available starting materials—a significant improvement over prior multi-stage processes requiring chromatographic purification stages.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)